Sendi PP - Search Results

1

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.

Sendi PP, Craig BA, Meier G, Pfluger D, Gafni A, Opravil M, Battegay M, Bucher HC. Sendi PP, et al. J Antimicrob Chemother. 1999 Dec;44(6):811-7. doi: 10.1093/jac/44.6.811. J Antimicrob Chemother. 1999. PMID: 10590283 Free article. Clinical Trial.

2

[Critical evaluation of a cost-effectiveness analysis].

Sendi PP, Bucher HC, Steurer J. Sendi PP, et al. Praxis (Bern 1994). 1998 Dec 3;87(49):1695-702. Praxis (Bern 1994). 1998. PMID: 9887670 German. No abstract available.

3

Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study.

Sendi PP, Bucher HC, Craig BA, Pfluger D, Battegay M. Sendi PP, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):376-81. doi: 10.1097/00042560-199904010-00008. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 10096582 Clinical Trial.

4

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.

Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Bucher HC, et al. AIDS. 1999 Mar 11;13(4):501-7. doi: 10.1097/00002030-199903110-00009. AIDS. 1999. PMID: 10197379 Clinical Trial.

5

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

Sendi PP, Bucher HC, Harr T, Craig BA, Schwietert M, Pfluger D, Gafni A, Battegay M. Sendi PP, et al. AIDS. 1999 Jun 18;13(9):1115-22. doi: 10.1097/00002030-199906180-00016. AIDS. 1999. PMID: 10397543

6

Rare AIDS-defining diseases in the Swiss HIV Cohort Study.

Burckhardt B, Sendi P, Pfluger D, Zimmerli W, Nüesch R, Bucher HC, Drewe J, Gyr N, Battegay M. Burckhardt B, et al. Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):399-402. doi: 10.1007/s100960050307. Eur J Clin Microbiol Infect Dis. 1999. PMID: 10442416

7

Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study.

Sendi PP, Craig BA, Pfluger D, Gafni A, Bucher HC. Sendi PP, et al. J Eval Clin Pract. 1999 Aug;5(3):283-95. doi: 10.1046/j.1365-2753.1999.00174.x. J Eval Clin Pract. 1999. PMID: 10461580

8

Uncertainty in decision models analyzing cost-effectiveness.

Craig BA, Black MA, Sendi PP. Craig BA, et al. Among authors: sendi pp. Med Decis Making. 2000 Jan-Mar;20(1):135-7. doi: 10.1177/0272989X0002000118. Med Decis Making. 2000. PMID: 10638547 No abstract available.

9

Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Sendi P, Palmer AJ, Gafni A, Battegay M. Sendi P, et al. Pharmacoeconomics. 2001;19(7):709-13. doi: 10.2165/00019053-200119070-00001. Pharmacoeconomics. 2001. PMID: 11548908

10

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients.

Battegay M, Vernazza PL, Bernasconi E, Flepp M, Sendi P, Erb P, Malinverni R, Jaccard C, Morgenthaler S, Bedoucha V, Hirschel B; Swiss HIV Cohort Study. Battegay M, et al. HIV Med. 2001 Jan;2(1):35-42. doi: 10.1046/j.1468-1293.2001.00047.x. HIV Med. 2001. PMID: 11737374 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters